NDA 209379 · Am Regent
Selenious Acid
Selenious Acid · Intravenous
Priority reviewLast checked: Nov 20, 2026Latest source record: Aug 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 30, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
15
5 Phase 3, 0 recruiting
FAERS reports
12
11 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 1, 2021.
Selenious Acid Injection is indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Selenious Acid Injectionis a trace element indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )
Mechanism: Selenious acid is converted in vivo to hydrogen selenide via glutathione-involved electron reductions. Hydrogen selenide acts as a selenium pool to form selenoproteins which include, but are not limited to, glutathione peroxidase, iodothyronine deiodinase, peroxidase and thioredoxins.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- SELENIOUS ACID · SELENIOUS ACID EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- SELENIOUS ACID · SELENIOUS ACID EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- SELENIOUS ACID · SELENIOUS ACID EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Selenious Acid" as an intervention, any sponsor and status, largest first.
- SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).Pivotal-lookingStatus unknown
Daren K. HeylandAcademic, hospital or other
NCT02002247 · 1,400 participants (planned) · Start Jan 2015 · Primary completion Feb 2021
Drug: sodium selenite; Placebo · For: Heart Disease
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 23 sites in all
- Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe SepsisPivotal-lookingCompleted
Kompetenznetz SepsisResearch network
NCT00832039 · 1,089 participants · Start Nov 2009 · Primary completion Mar 2013
Drug: sodium-selenite; Placebo · For: Severe Sepsis; Septic Shock
Sites: Aachen, Germany; Augsburg, Germany; Berlin, Germany · 35 sites in all
- Selenium in the Treatment of Arsenic Toxicity and CancersPivotal-lookingCompleted
Texas Tech UniversityAcademic, hospital or other
NCT01442727 · 819 participants · Start Dec 2006 · Primary completion Apr 2009
Drug: sodium selenite; placebo · For: Arsenical Melanosis; Arsenical Keratosis; Arsenical Cancers and 4 more
Sites: Kalibari Town, Bangladesh
- Peripartum Cardiomyopathy in Nigeria RegistryPivotal-lookingCompleted
Aminu Kano Teaching HospitalAcademic, hospital or other
NCT03081949 · 100 participants · Start Jun 12, 2017 · Primary completion Jun 30, 2019
Drug: Oral Sodium Selenite 200 µg/day for 3 months · For: Peripartum Cardiomyopathy
Sites: Kano, Nigeria · 2 sites in all
- Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.Pivotal-lookingStatus unknown
CHRISTUS HealthAcademic, hospital or other
NCT04869579 · 100 participants (planned) · Start Aug 15, 2021 · Primary completion Nov 15, 2021
Drug: Selenium (as Selenious Acid) · For: Covid19
Sites: Longview, Texas
- High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral NeuropathyPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT04201561 · 68 participants (planned) · Start Dec 24, 2019 · Primary completion Apr 30, 2023
Drug: sodium selenite pentahydrate; Normal saline and 1 more · For: Chemotherapy-induced Peripheral Neuropathy; Recurrent Ovarian Carcinoma; Ovarian Cancer and 2 more
Sites: Seoul, South Korea
Centre Hospitalier de MeauxAcademic, hospital or other
NCT00207844 · 60 participants · Start Jan 2002
Drug: Selenium as sodium selenite · For: Septic Shock; Severe Sepsis
Sites: Argenteuil, France; Châlons-en-Champagne, France; Garches, France · 7 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT00188604 · 34 participants (planned) · Start Jan 2004 · Primary completion Jan 2009
Drug: sodium selenite · For: Breast Neoplasms; Lymphedema
Sites: Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- plasma cell myeloma5
- diarrhoea2
- cerebral palsy1
- cholangitis1
- circumstance or information capable of leading to medication error1
- fatigue1
- hypersensitivity1
- infection1
- internal haemorrhage1
- nausea1
- neuropathy peripheral1
- pneumonia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2026 | 2 |
Recalls
1 FDA enforcement reports for this application.
Jul 24, 2026 · Class II · Ongoing
Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Influence of selenium supplementation on patients with inflammation: A pilot double blind randomized study.
Freitas RGBON, Nogueira RJN, Cozzolino SMF, et al. · Nutrition 2017 · Randomized Controlled Trial
- Phase I trial of selenium plus chemotherapy in gynecologic cancers.
Song M, Kumaran MN, Gounder M, et al. · Gynecol Oncol 2018 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Randomised clinical trial of parenteral selenium supplementation in preterm infants.
Daniels L, Gibson R, Simmer K · Arch Dis Child Fetal Neonatal Ed 1996 · Clinical Trial, Randomized Controlled Trial
- High-dose selenium for critically ill patients with systemic inflammation: pharmacokinetics and pharmacodynamics of selenious acid: a pilot study.
Manzanares W, Biestro A, Galusso F, et al. · Nutrition 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Am Regent
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.